1. Introduction {#sec1}
===============

After its zoonotic emergence in China, during November--December 2019 \[[@bib1], [@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8]\], the Coronavirus Disease 2019 (COVID-19), caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) \[[@bib9]\], spread significantly into other countries in Asia \[[@bib10], [@bib11], [@bib12], [@bib13], [@bib14]\]. Then, to other continents such as the Pacific region \[[@bib15]\], North America \[[@bib16],[@bib17]\], Europe \[[@bib18], [@bib19], [@bib20], [@bib21], [@bib22]\], and even Africa \[[@bib23], [@bib24], [@bib25], [@bib26]\].

On February 25, 2020, a Brazilian traveller returned home from Lombardy, northern Italy, to São Paulo, Brazil, presenting fever, dry cough, sore throat, and coryza, being tested by the real-time reverse-transcriptase polymerase chain reaction (rRT-PCR), and with a positive result, becoming the first confirmed case in Latin America \[[@bib27], [@bib28], [@bib29]\]. After it, other countries in Latin America, such as Mexico \[[@bib30]\], Costa Rica, Honduras \[[@bib31]\], Panama, in Central America, as well as Argentina, Chile, Colombia, among others in South America, including also on March 2, 2020, Bolivia, have received travellers, and diagnosed imported cases of COVID-19 in their territories.

In most of the countries of Latin America, confirmed cases have been specially imported from Italy but also from Spain. Although this scenario, no case reports or series from South America are yet available in scientific journals.

During March 2--15, 2020, the first 12 cases of SARS-CoV-2-laboratory confirmed, arrived and were diagnosed in different areas of Bolivia. Herein, we report the main clinical findings and epidemiological features of them.

2. Methods {#sec2}
==========

Bolivia is a South American country constituted by nine departments (main administrative level), 112 provinces (second administrative level) and 337 municipalities (third administrative level) ([Fig. 1](#fig1){ref-type="fig"} ). The territory presents climatic, geographic, social, and epidemiological conditions suitable for the transmission of many infectious diseases ([Fig. 1](#fig1){ref-type="fig"}). Before SARS-CoV-2 arrival, Influenza and RSV, among other respiratory viruses, represent significant causes of hospitalization in different cities of the country, especially among children under one year of age \[[@bib32], [@bib33], [@bib34]\].Fig. 1Relationship and contacts between the cases of SARS-CoV-2 infection/COVID-19 in Bolivia, March 2--15, 2020.Fig. 1

For this observational, retrospective and cross-sectional study, the epidemiological data records were collected from the Hospitals and the Ministry of Health of Bolivia, obtaining the clinical and epidemiological data of the COVID-19 cases that were laboratory-diagnosed during March 2--15, 2020. Samples were tested by rRT-PCR to SARS-CoV-2 at the Laboratory of the National Center of Tropical Diseases (CENETROP), 2020, following the protocol Charité, Berlin, Germany \[[@bib35]\].

Given the small number of cases, the summary of continuous variables considered the median and interquartile ranges (IQR). All analyses were performed with the statistical software Stata®14IC, licensed for Universidad Tecnológica de Pereira.

3. Results {#sec3}
==========

During March 2--15, 2020, 152 suspected cases were investigated in Bolivia, especially from international travellers, most from China, Italy and Spain. Although active enhanced surveillance for respiratory tract infection begun in January 2020, considering the international warning for the 2019 novel Coronavirus, later designated as COVID-19. The first suspected cases were investigated between February 2, and March 1, 2020, including ten travellers, all negative by rRT-PCR in that period.

A total of 12 cases (7.9%) were diagnosed with COVID-19 at different departments of Bolivia ([Fig. 1](#fig1){ref-type="fig"}). The median age of patients was 39.0 y-old (IQR 25.3--43.4); six of them were male. On March 2th, 2020, a 64-year-old woman (Case 1), a Bolivian from Oruro, visiting Lombardy, Italy, during the last 14 days, with no previous history of comorbidities, returned to Bolivia, arriving at Santa Cruz, then travelling to La Paz, Cochabamba, and finally to her home in Oruro. She presented at the outpatient department of the General Hospital of Oruro, on March 3rd, 2020, complaining with fever, cough, vomiting, malaise and abdominal pain, but with no other significant signs or symptoms. Nasopharyngeal swabs obtained, and she isolated at home. Her samples tested positive for SARS-CoV-2 on rRT-PCR assays at the Laboratory of the National Center of Tropical Diseases (CENETROP) on March 10th, 2020. She was in contact with seven relatives, six in Oruro (Cases 3--7 and 10) and one in Cochabamba (Case 8), all investigated and tested positive ([Fig. 1](#fig1){ref-type="fig"}) ([Table 1](#tbl1){ref-type="table"} ). Although negative, cases have been investigated in the rest of the departments of Bolivia ([Fig. 1](#fig1){ref-type="fig"}), including initial phone call -telemedicine- for over 15,000 individuals in the first month.Table 1Clinical and epidemiological characteristics of cases of SARS-CoV-2 infection/COVID-19 in Bolivia, March 2--15, 2020.Table 1\
CaseDate of March 2020DepartmentAgeSexDate Symptoms Initiated, 2020Date Consultation (month/day)DaysHospitalizationClinical manifestationsComorbidities or historyTraveller fromStarted dayReturning dayLong of travelLink to casesSampling placeFeverCoughMalaiseVomitingAbdominal PainTachypneaMyalgiaSore throatDiarrhoeaCephaleaConjunctival injection18thOruro64F3/23/31OutpYYYYYNNNNNNNItalia3/13/23.01 yearsNHospital29thSanta Cruz60F2/293/88HospYYYNNYNNNNNHTAItalia2/73/830 daysNHospital310thOruro41F3/93/90OutpYNNNNNYNNNNN--------C1Home410thOruro13MUnknown3/8UnknownOutpNYNNNNNYNNNN--------C1Home510thOruro44M3/103/100OutpNYNNNNYNNNNN--------C1Home610thOruro39M3/23/119OutpNYNNNNNYNNNN--------C1Home710thOruro39FUnknown3/10UnknownOutpYYNNNNNNNNNN--------C1Home811thCochabamba43M3/63/93OutpYYNNYNYYYNYPrevious CAP--------C1Home911thSanta Cruz27M3/93/112OutpYNNNNNYNNYNNSpain2/233/814 daysNHospital1011thOruro18M3/83/113OutpYYYNNNNNYNNN--------C1Home1113thSanta Cruz20F3/93/101OutpYYNNNNNYNNNNSpain2/53/1135 daysNHome1215thSanta Cruz30F3/133/152OutpYNYNNNYYNYNNSpain3/93/112 daysNHospital[^2]

In Santa Cruz de la Sierra, four cases were confirmed, three of them travellers from Italy and one from Spain ([Fig. 1](#fig1){ref-type="fig"}) ([Table 1](#tbl1){ref-type="table"}). None of these was initially detected by border officials, as suspected, but in hospitals. The median time between the initial symptoms and consultation was two days (IQR 0.25--3.00 days). From the total, only one patient was hospitalized, and the rest were isolated at home initially per 14 days. The hospitalized patient was a 60 y-old woman with hypertension, then as presenting more two risk factors, decided for close clinical observation.

Nine patients presented fever, and cough, five sore throat, and myalgia, among other symptoms ([Table 1](#tbl1){ref-type="table"}). Only two patients reported previous comorbidities, hypertension and community-acquired pneumonia ([Table 1](#tbl1){ref-type="table"}). None of the patients was previously immunized against Influenza.

Chest radiographs obtained for the patient showed no abnormalities. Real-time RT-PCR and ELISA assays for influenza A and B viruses, NS1 antigen rapid tests for dengue viruses, chikungunya, and Zika, were negative in all cases.

Patients did not receive antiviral anti-SARS-CoV-2 treatment, especially, as most of them were managed at home, symptomatically, and without further need of specialized medical care.

4. Discussion {#sec4}
=============

Emerging infectious diseases, such as is the case of COVID-19 are currently prone for the risk of epidemics, or even, as has been this case, to became a Public Health Emergency of International Concern (PHEIC), and later a pandemic, as declared by the World Health Organization (WHO) \[[@bib36], [@bib37], [@bib38], [@bib39]\].

In this context, Latin America was the last significant region where COVID-19 arrived \[[@bib27],[@bib40]\]. In this case, coming mainly from two European countries, Italy and Spain \[[@bib18], [@bib19], [@bib20], [@bib21], [@bib22]\]. In Bolivia, the first two cases came from Italy. Especially in the north of that country, significant epidemics are going on. For the moment of the arrival of the first Bolivian COVID-19 case, there were 7,375 cases in Italy, with 366 deaths. The ninth, eleventh, and twelfth cases came from Spain. For the moment of the arrival of these cases, the last on March 15, 2020, there were 7,988 cases in Spain. That issue has been a common trend in Latin America now, imported cases from Italy and Spain \[[@bib27],[@bib41],[@bib42]\]. This highlights the relevance of the spread of the COVID-19 due to population movements that has affected Bolivia, but also countries in South America, and most in the Latin American and the Caribbean region.

As has occurred in other affected countries elsewhere, there is a risk of local clusters of transmission from imported cases \[[@bib1],[@bib43], [@bib44], [@bib45], [@bib46]\]. Precisely, the first case in Bolivia, originated the transmission to other seven cases in two different departments of the country, as the patient travelled to Santa Cruz, Cochabamba, La Paz and Oruro ([Fig. 1](#fig1){ref-type="fig"}). Close contact with active cases of COVID-19 represents a significant risk for SARS-CoV-2 transmission, even during the asymptomatic or presymptomatic stage, especially for relatives or friends \[[@bib19],[@bib46], [@bib47], [@bib48], [@bib49]\].

None of the cases in this study required intensive care unit (ICU). The hospitalized case evolved good and was only hospitalized due to risk factors (age and hypertension) \[[@bib1], [@bib2], [@bib3], [@bib4],[@bib6],[@bib16],[@bib50]\].

The clinical manifestations of these patients were according to the expected as reported in the literature \[[@bib50]\], presenting mainly fever, and cough, among other symptoms. Ten of the twelve cases were younger than 60 y-old, and with no risk factors, except in two cases with hypertension and a history of community-acquired pneumonia. Then, the clinical evolution was favorable with no complications and no deaths among these patients. Early healthcare with appropriate training of healthcare works would be critical to keeping mostly this in a similar trend for future cases in the country that is now taken severe actions, such as home isolation and quarantine \[[@bib51], [@bib52], [@bib53], [@bib54]\], primarily to protect those with risk factors. According to the National Institute of Statistics of Bolivia, for 2019, there were 11,513,101 inhabitants. From them, 10.19% corresponded to people older than 60 years-old \[[@bib55]\]. For some risk factors, such as diabetes mellitus, Bolivia is amongst the country with the lowest prevalence, around 6.6% in 2016 \[[@bib56]\]. However, is estimated that a third of the Bolivian population presents high blood pressure \[[@bib57]\], which is considered among the most prevalent risk factors in patients with COVID-19, for worse clinical progression \[[@bib50]\], then the case 2 in Santa Cruz, was hospitalized for close monitoring while having age and hypertension as risk factors.

Bolivia is a developing country with limited resources. In this scenario, the previous overlapping health events, such as dengue \[[@bib27]\], chikungunya, Zika, hantavirus and even hemorrhagic fevers caused by arenaviruses \[[@bib58], [@bib59], [@bib60], [@bib61]\], as well as regular viral respiratory infections \[[@bib32], [@bib33], [@bib34]\], may pose a challenge for diagnosis, and the healthcare together the ongoing COVID-19 outbreak.

There has been a rapid surge in research in response to the outbreak of COVID-19 \[[@bib62]\]. During this early period, published research primarily explored the epidemiology \[[@bib63]\], causes, clinical manifestation and diagnosis \[[@bib64]\], as well as prevention and control of the novel coronavirus. Although these studies are relevant to control the current public emergency, more high-quality research is needed to provide valid and reliable ways to manage this kind of public health emergency in both the short- and long-term, including therapeutic options \[[@bib65], [@bib66], [@bib67], [@bib68], [@bib69], [@bib70], [@bib71]\].

During the current phase of COVID-19 outbreak in Bolivia, only of imported cases, all of them are being tested by rRT-PCR. However, the question is if the spread occurs rapidly in the country, with community-transmission as is now observed in other countries in the continent \[[@bib72], [@bib73], [@bib74]\], Bolivia, as well as other low- and middle-income countries in the region, e.g. Haiti, Venezuela \[[@bib75]\], Nicaragua, among others, will not be able to afford large-scale diagnostics \[[@bib24]\]. Therefore, in the absence of testing, triage based on clinical case definition or presumptive diagnosis should be prioritized. A proposal for surveillance at that point, if diagnostics are limited, is to develop a definition of a clinical confirmed case. As occurred with chikungunya, and Zika, in most countries in Latin America, this would be "a patient with fever, cough and other respiratory symptoms, not explained by other etiological agents or causes, that is diagnosed in a municipality where at least a laboratory-confirmed case was identified" \[[@bib76], [@bib77], [@bib78]\].

The number of patients that may require ventilatory support and attention at an intensive care unit (ICU) may collapse the health system of larger countries. In the case of Bolivia, there are only 35 ICU beds. Then, as expected, the health authorities are working on the general beds that can be rapidly converted to ICU beds and some general hospitals to be converted into critical care hospitals. Additional physicians and nurses are now widely trained in critical care medicine and specifically on COVID-19 in order to answer the epidemic. A national telehealth program is running for multiple purposes, including training on COVID-19. Albeit that, it is debatable whether countries such as Bolivia can fund the additional cost of critical care units from our limited health budgets \[[@bib24],[@bib27]\], that need to attend not only the epidemic of COVID-19 but also other non-communicable diseases as well as communicable diseases, such as dengue, diarrhoea, malaria, HIV, tuberculosis, among many other diseases \[[@bib27],[@bib75]\].

Finally, in the absence of vaccines and specific treatments available and approved for COVID-19, the only available public health tools to control person-to-person transmittable diseases are isolation and quarantine, social distancing, and community containment measures, and this is now in place in Bolivia, as well as in most countries of Latin America \[[@bib54],[@bib79]\]. There is an urgent need to train most of the healthcare workforce on biosecurity, isolation, and quarantine, in order to be massively applied in the country. If these measures are implemented soon, more possibilities to control spreading will have the countries, which is even critical in countries, such as Bolivia, with limited resources.

In conclusion, while the global awareness and response to the COVID-19 pandemic are well known, each country faces its considerations and scenarios to face the epidemic in their territories. In the case of Bolivia, the less developed nation of South America, national and international cooperation, advise and support, lead to enhance surveillance and early case detection of COVID-19, scaling up the training activities at the healthcare sector and the community for proper education as well as quarantine. In this report, the first 12 confirmed cases were analyzed, showing that most of the evolve positively with no severe disease nor fatalities. Nevertheless, preparedness for a significant epidemic, as is going on in other countries, and the deployment of response plans for it, in the country is now taking place to mitigate the impact of the COVID-19 pandemic in the population.

Preparedness in South America should include the increase in the diagnostic capacity for rapid testing for the virus, including not only imported but also secondary and tertiary cases. It is important to avoid the delay from identification of suspected cases to their confirmation and isolation, in order to affect the possible disease transmission \[[@bib25]\]. Also, there is a need for improvement of the volume of personnel trained to run such tests, and to warrant an adequate stock of materials needed to do them. Health authorities should train, equip, and strengthen the diagnostic capacities of hospital laboratories close to infectious disease and emergency departments to reduce the time to deliver results, manage confirmed cases and contacts more rapidly, and preserve strict infection control measures \[[@bib25]\]. Finally, in the differential diagnosis with other febrile conditions, especially in Latin America, also coinfections with dengue \[[@bib75]\] and with respiratory viruses, such as Influenza and Metapneumovirus \[[@bib80], [@bib81], [@bib82]\], among others, already reported together with SARS-CoV-2, should be considered.

5. Limitations {#sec5}
==============

The main limitation of our study is the lack of long follow up of the patients, but this analysis is a rapid preliminary study for the outbreak assessment in Bolivia, focused on epidemiological and clinical aspects. Secondly, still, there are no available serological tests to assess the antibody response. Third, due to constraining in the use of the rRT-PCR, only initial testing was provided, although after ceased of symptoms, for the case hospitalized, it will be repeated to assess if became negative. More comprehensive contact tracing for these cases should be performed to assess the possibility of community transmission. Finally, soon, Bolivia will also need to have sequencing and phylogenetic studies that would be useful as this may diverge from other SARS-CoV-2 isolates or strain, that even, would be related to clinical evolution and outcomes.
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[^1]: [www.lancovid.org](http://www.lancovid.org){#intref0010}.

[^2]: F, Female; M, Male; Outp, Outpatient; Hosp, Hospitalization; Y, Yes; N, No; HTA, hypertension; CAP, Community-acquired pneumonia; C1, Case 1.
